Glioblastoma is the deadliest primary brain tumor, and fewer than 7% of patients survive 5 years even after surgery, radiation, and chemotherapy. Several features make it difficult to treat: the tumor heterogeneity, it adapts quickly to resist drugs, and the blood-brain barrier keeps most agents from reaching it. These...
Saniyah Shaikh, Arshiya Akbar, Ismail A. Abdullah et al.· Frontiers in Nutrition· 0 citations
Patient‐derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long‐standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three‐dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural...
Abdullah Jabri, Mohamed Alsharif, Abdulaziz Mhannayeh et al.· Cell Biochemistry and Functi...· 0 citations
A modular aptamer-guided LNP platform to enable hepatocyte-selective genome editing through an LDLR-independent route is designed and validated and a validated LDLR-null hepatocyte model is validated for studying LDLR-dependent biology and disease.